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Abstract
Background: Honokiol is a major bioactive compound extracted from Magnolia. The present
study was designed to determine whether liposomal honokiol has the antitumor activity against
human lung cancer as well as potentiates the antitumor activity of cisplatin in A549 lung cancer
xenograft model, if so, to examine the possible mechanism in the phenomenon.
Methods: human A549 lung cancer-bearing nude mice were treated with liposomal honokiol,
liposomal honokiol plus DDP or with control groups. Apoptotic cells and vessels were evaluated
by fluorescent in situ TUNEL assay and by immunohistochemistry with an antibody reactive to
CD31 respectively.
Results: The present study showed that liposomal honokiol alone resulted in effective suppression
of the tumor growth, and that the combined treatment with honokiol plus DDP had the enhanced
inhibition of the tumor growth and resulted in a significant increase in life span. The more apparent
apoptotic cells in the tumors treated with honokiol plus DDP was found in fluorescent in situ
TUNEL assay, compared with the treatment with control groups. In addition, the combination of
honokiol and DDP apparently reduced the number of vessels by immunolabeling of CD31 in the
tissue sections, compared with control groups.
Conclusion: In summary, our data suggest that honokiol alone had the antitumor activity against
human lung cancer in A549 lung cancer xenograft model, and that the combination of honokiol with
DDP can enhance the antitumor activity, and that the enhanced antitumor efficacy in vivo may in
part result from the increased induction of the apoptosis and the enhanced inhibition of
angiogenesis in the combined treatment. The present findings may be of importance to the further
exploration of the potential application of the honokiol alone or the combined approach in the
treatment of lung carcinoma.
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Background
Lung cancer is the leading cause of cancer related death in
both males and females. Non-small cell lung cancer
(NSCLC) comprises approximately 75–80% of all lung
cancers. Despite aggressive approaches made in the ther-
apy of lung cancer in the past decades, the prognosis of
NSCLC remains poor, with 5-year survival rates of 5–14%,
even if treated with surgery, radiotherapy and/or chemo-
therapy [1-3]. Efforts are therefore continuing to develop
new and less toxic therapeutic approaches for the treat-
ment of lung cancer.
Honokiol is a major bioactive compound extracted from
Magnolia [4]. It has been reported that honokiol induces
apoptosis and inhibits the in vitro growth of a variety of
human cancer cell lines such as leukemia cell lines HL-60
and Molt 4B; colon cancer cell line RKO; lung cancer cell
line CH27 [5-9]. Honokiol also exhibited the potent anti-
proliferative activity against endothelial cells transformed
endothelial cell line SVR and the primary human
endothelial cells in vitro [4]. These findings suggest that
honokiol has both anti-angiogenic and anti-tumor activ-
ity in vitro. Furthermore, there are several reports of in
vivo antitumor activity of honokiol against skin tumors
and SVR angiosarcoma in a mouse model [4,10]. How-
ever, little is known about the antitumor activity in lung
cancer in an animal model.
Cisplatin (DDP) remains the most widely used first-line
element of cytotoxic chemotherapy to solid tumors [11].
However, the efficacy of DDP based on the treatment is
limited in curing most solid tumors due to dose-depend-
ent toxicity. Therefore, several new therapeutic strategies
under investigation involve modulation of cellular chem-
osensitivity, including the inhibition of tumor neovascu-
larization, reversing tumor resistance, and increasing
therapeutic effects of chemotherapy [12,13].
Because of differences in the possible mechanisms of
action and toxicity profiles of honokiol and cisplatin, the
combination of the above two agents may have clinical
potential. The present study was designed to determine
whether liposomal honokiol has the antitumor activity
against human lung cancer as well as potentiates the anti-
tumor activity of cisplatin in A549 lung cancer xenograft
model, if so, to examine the possible mechanism in the
phenomenon, and to provide some potential implica-
tions for the treatment of human lung cancer.
Methods
Agents
Polyethylene glycol 4000-phosphoethanolamine (PEG-
PE), cholesterol and PC were purchased from Sigma
Chemical Co, (St. Louis, MO). Cisplatin (DDP) was pur-
chased from QiLu pharmaceutical factory. A rat anti-
mouse CD31 monoclonal antibody was purchased from
BD Biosciences Co (PharMingen, San diego, CA). In situ
Cell Death Detection kit was purchased from Roche Co.
(Promega, Madison, WI). Honokiol was separated and
purified by High-speed counter-current chromatography
from cortex Magnoliae Officinalis, as reported previously
[14]. Its purity and identification were analyzed by high
performance liquid chromatography and nuclear mag-
netic Resonance. The purities of the isolated honokiol
were more than 99.6%.
Preparation of liposomal honokiol
The preparation of PEG-modified Liposomal honokiol
was modified as reported previously by us [15]. Briefly,
the mixture of PC, cholesterol, PEG4000-PE and honokiol
in weight ratios of 1:0.15:0.24:0.22 were dissolved in 15
ml chloroform/methanol at a ratio of 3:1 (v/v). The mix-
ture was gently warmed to 40°C in a round-bottomed
flask, and the solvent was evaporated under vacuum in a
rotary evaporator until a thin lipid film was formed. The
dried lipid films were left overnight and sonicated in 5%
glucose solution at constant container followed by con-
centrated and lyophilized. The preparation of empty free
liposome was the same way as the liposomal honokiol
withour honokiol addition. The final liposomal honokiol
was small multilamellar liposomes in a size range of 130
± 20 nm. Lyophilized liposomal honokiol and free lipo-
some were dissolved in 5% glucose water for vitro and
vivo studies.
Animal tumor models and treatment
Human A549 lung adenocarcinoma cells were obtained
from the American Type Culture Collection (ATCC, Man-
assas, VA). The cells were maintained in RPMI1640 (Life
Technologies, Bedford, MA) containing 10% heat-inacti-
vated FCS, 100 units/mL penicillin, and 100 units/mL
streptomycin in a humid 5% CO2 incubator at 37°C.
Human A549 tumor models were established in 6 – 8
weeks old, athymic nude mice (SPF grade). Athymic nude
mice were inoculated with A549 cells/0.1 ml (1.0 × 107)
s.c. All these mice were obtained from Sichuan University
Animal Center (Sichuan, Chengdu, China). All studies
involving mice were approved by the institute's animal
care and use committee.
In our preliminary experiment, we have performed a
series of experiment in order to determine the optimum
doses for the two agents. Human A549 lung cancer cells
(1.0 × 107) were injected s.c.. Once tumors were palpable,
mice were randomly assigned into each group (n = 5
mice/group). Treatments were given i.p. with PBS, lipo-
some, free honokiol alone, or liposomal honokiol at dif-
ferent doses of 1 to 50 mg/kg every day for 21 days,
respectively.
In the next set of the experiment, 549 lung cancer cells
(1.0 × 107) were injected s.c.. Seven days later, onceBMC Cancer 2008, 8:242 http://www.biomedcentral.com/1471-2407/8/242
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tumors were palpable, mice were randomly divided into
each group. Treatments were given i.p. with liposomal
honokiol (25 mg/kg) every day for 21 days or with PBS,
liposome or cisplatin (5 mg/kg) or free honokiol alone as
a control. In combination treatment, liposomal honokiol
is injected 4 hours later after cisplatin administration.
DDP (5 mg/kg) was given i.p. twice a week for two weeks,
as we reported previously [13]. In the other experiments,
the courses are repeated every 4 weeks, namely, treatment
was stopped for 1 week followed by a new cycle of ther-
apy. Survival time and tumor volume were observed.
Tumor size was determined by caliper measurement of
the largest and perpendicular diameters. Tumor volume
was calculated according to the formula V = 0.52ab2 [14].
Pharmacokinetic studies
Pharmacokinetic studies were performed as reported pre-
viously by us [15]. Briefly, on day 15 after the inoculation
of the tumor, the liposomal honokiol or the free honokiol
dissolved in DMSO was given i.v. to these mice at a dose
of 25 mg/kg. Mice were sacrificed at defined time points
(at 5 and 30 min, and at 1, 5, 12, 24, and 48 h after the
administration of honokiol). At each time point, four
mice were sacrificed and their blood was collected from
the orbital cavity vein plexus, heparinized, and centri-
fuged to obtain the plasma. The tumor, kidney, liver, lung,
intestine, heart, and spleen tissues were excised and
weighed, and homogenized. Plasma and the homoge-
nized organs were added to accetonitrile, and supernatant
fluid was collected and evaporated to dryness. The dry res-
idues were dissolved in methanol for high-performance
liquid chromatography analyses.
Quantitative assessment of apoptosis
Quantitative assessment of apoptosis was performed as
reported previously by us [13,15]. Briefly, terminal deox-
ynucleotidyl transferase – mediated nick-end labeling
staining was done using an in situ cell death detection kit
(Roche Molecular Biochemicals) following the manufac-
turer's protocol. It is based on the enzymatic addition of
digoxigenin nucleotide to the nicked DNA by terminal
deoxynucleotidyl transferase. In tissue sections, five
equal-sized fields were randomly chosen and analyzed.
Density was evaluated in each field, yielding the density of
apoptotic cells (apoptosis index).
Detection of CD31 by immunohistochemistry
The anti-angiogenesis effects were determined by immu-
nohistochemistry with an antibody reactive to CD31 as
described previously by us [15]. Briefly, frozen sections
were fixed in acetone and incubated with a monoclonal
goat anti-rabbit CD31 antibody (1:400; Santa Cruz Bio-
technology) at 4°C overnight, followed by incubation
with biotinylated polyclonal rabbit anti-rat antibody
(1:200; Vector, Burlingame, CA) in a humidified chamber
for 1 h, and then were immersed in 0.3% H2O2 in abso-
lute methanol for 15 min to block endogenous peroxi-
dase. Positive reaction was visualized using 3, 3-
diaminobenzidine as chromagen (DAB substrate kit; Vec-
tor). Sections were counterstained with hematoxylin and
mounted with glass coverslips. Vessel density was deter-
mined by counting the number of microvessels per high-
power field in the section. Then tissue sections were visu-
alized in an Olympus microscope to determine microves-
sel density (MVD).
Observation of potential toxicity
The toxicities of the treatment regimens were estimated by
changes in the incidence of drug-associated death. Gross
measures, such as weight loss, ruffling of fur, life span,
behavior, and feeding were studied. Tissues of heart, liver,
spleen, lung, kidney, brain, bone marrow, etc. were also
fixed in 10% neutral buffered formalin solution and
embedded in paraffin. Sections of 4 μm were stained with
H&E. Blood was obtained from the tail vein for complete
blood count and differentials as well as enzyme analysis.
Statistical analysis
For comparison of individual time points, different results
between the groups were reported as means ± SD and
tested by performing one-way analysis of variance
(ANOVA) and a log-rank test. The statistical significance
level was set as p less than 0.05.
Results
Tumor growth inhibition
In order to determine the optimum doses for honokiol,
human A549-bearing nude mice were treated with lipo-
somal honokiol at different doses ranged from 1 to 50
mg/kg. The mice treated with 15 and 10 mg/kg liposomal
honokiol showed different inhibiting response to tumor
compared with control group, including free liposome
group and PBS controls. When the dose of liposomal
honokiol was elevated to 25 mg/kg, there are significantly
inhibitions of tumor growth, whereas there was no further
enhancement of the antitumor activity at the dose of 50
mg/kg. Hence, we selected the dose of 25 mg/kg as opti-
mum dose for the combination treatment with cisplatin.
In the next set of experiment, Mice were treated with intra-
peritoneal injection of liposomal honokiol at 25 mg/Kg
once daily for 21 days and/or administration of DDP i.p.
twice a week for two weeks (5 mg/kg, starting at 4 hours
before the initiation of liposomal honokiol) or appropri-
ate controls 0.2 ml PBS or liposome alone at the same
time point. Tumor volume and life span of mice assay
showed that both liposomal honokiol and DDP individ-
ually resulted in the antitumor activity (Figure 1A and
1B). Combined treatment with liposomal honokiol plus
DDP had a superior suppression of the tumor growth
antitumor (Figure 1A). For example, the combined group
showed markedly regression of tumor volume (352.43 ±
159.98 mm3) on the day 40, compared with the controlBMC Cancer 2008, 8:242 http://www.biomedcentral.com/1471-2407/8/242
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groups, including PBS (3317.28 ± 380.46 mm3), lipo-
some (3215.32 ± 295.80 mm3), liposomal honokiol
(1028.72 ± 190.59 mm3) or cisplatin (1264.27 ± 121.12
mm3) alone. The combination of liposomal honokiol
therapy with DDP also resulted in a significant increase in
life span (Figure 1B). Similar results were also found in
LLC Lewis lung cancer model in C57BL/6 mice (data not
shown).
Inhibition of angiogenesis by combination Liposomal 
honokiol plus DDP
Having witnessed apparent antitumor activity in A549
human lung cancer model, we further quantified vessel
density as measures of angiogenesis by immunolabeling
of CD31 in tissue sections. The combination of liposomal
honokiol and DDP apparently reduced the number of ves-
sels compared with control groups (Figure 2), including
liposome, PBS, liposomal honokiol, DDP alone (P <
0.05). Angiogenesis was also inhibited in the treatment
with honokiol or DDP alone (Figure 2).
In vivo Induction of apoptosis with the combined 
Treatment
To explore the role of liposomal honokiol on the apopto-
sis of tumor cells, we examined the apoptosis-related
molecular marker on tumor sections. An apoptosis detec-
tion kit was used to detect early DNA fragmentation asso-
ciated with apoptosis. The treatment with liposomal
honokiol or DDP alone affected the apoptosis rate of
tumor cells, whereas the density of the apoptotic cancer
cells apparently increased after the combined therapy
(Figure 3). Data represent the mean apoptotic index ± SD
of cancer cells as percent normalized to apoptotic index of
cancer cells.
The plasma honokiol concentrations of liposomal honokiol 
and free honokiol
Plasma honokiol concentrations in tumor-bearing mice
were determined after i.v. injection of 25 mg/kg liposomal
honokiol and free honokiol. The pharmacokinetics of
liposomal honokiol differed significantly from those of
free honokiol. Liposomal honokiol prolonged blood cir-
culation times in tumor-bearing mice in comparison with
free honokiol (Figure 4). The plasma honokiol concentra-
tions remained above 30 and 10 μg/ml for 24 and 48
hours study respectively in liposomal honokiol-treated
mices, whereas those fell quickly, with less than 5 μg/ml
by 12 hours in free honokiol-treated mice,.
The representative experiment of tumor suppression and survival advantage in mice Figure 1
The representative experiment of tumor suppression and survival advantage in mice. Mice were treated i.p. with liposomal 
honokiol (25 mg/kg) every day for 21 days. In the combination treatment, liposomal honokiol is injected 4 hours later after cis-
platin administration. (5 mg/kg, i.p. twice a week for two weeks). In addition, the control groups including PBS, liposome or cis-
platin (5 mg/kg) alone. A, suppression of s.c. tumor growth in mice. The combination of liposomal honokiol with DDP can 
enhance the inhibition of the tumor growth. The results were expressed as the mean volume ± SD; B, a significant increase in 
survival in combined treatment mice compared with the controls. Liposomal honokiol plus cisplatin (solid square), liposomal 
honokiol (open triangle), cisplatin (solid triangle), liposome (open circles) and PBS (solid circle).BMC Cancer 2008, 8:242 http://www.biomedcentral.com/1471-2407/8/242
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Observation of the potential toxicity
The animals were particularly investigated for potential
toxicity. None of pathologic changes in liver, lung, kidney,
etc. were found by microscopic examination after the
administration of liposomal honokiol or liposomal
honokiol plus DDP. No adverse consequences were
shown in gross measures, such as weight loss, ruffling of
fur, life span, behavior, or feeding. For the evaluation of
the effects on hematopoiesis, animals were subjected to
complete peripheral blood counts and differentials. Anal-
ysis of peripheral blood revealed that no significant differ-
ence was observed between DDP-treated and the
combined treatment group (Table 1). In addition, the
treatment with liposomal honokiol alone did not show
the decrease of blood cells, compared with saline control
group. Our data suggested that the traditional chemother-
apeutic DDP in the combination with honokiol may be
concurrently practicable with less host toxicity.
Discussion
It has been reported that honokiol induces apoptosis and
inhibits the in vitro growth of a variety of human cancer
cell lines [5-9]. Honokiol also shows the potent anti-pro-
liferative activity against endothelial cells transformed
endothelial cell line SV and the primary human endothe-
lial cells in vitro [4]. These findings suggest that honokiol
has both anti-angiogenic and anti-tumor activity. In the
present study, several observations have been made con-
cerning the induction of apoptosis, the inhibition of ang-
iogenesis, antitumor activity and the combined treatment
with liposomal honokiol plus DDP. The present study
has, to our knowledge, for the first time demonstrated
that liposomal honokiol had the inhibitory effect on the
in vivo growth of human lung cancer in A549 lung cancer
xenograft model, and that liposomal honokiol plus DDP
induced the enhanced antitumor activity and augmented
the induction of apoptosis in lung cancer cells in vivo as
well as the inhibition of the angiogenesis.
Although the exact mechanism by which the combination
of liposomal honokiol with DDP can enhance the antitu-
mor activity remained to be determined, the enhanced
antitumor efficacy in vivo may in part result from the
increased induction of the apoptosis as well as inhibition
The representative experiment of inhibition of the angiogenesis within tumors Figure 2
The representative experiment of inhibition of the angiogenesis within tumors. Mice bearing the established tumors were 
administered i.p. with liposomal honokiol (25 mg/kg) every day for 21 days, and/or cisplatin (5 mg/kg, i.p. twice a week for two 
weeks).or liposome or PBS alone. Vessel density was determined by counting per high-power field in the sections stained with 
an antibody reactive to CD31, as described in Materials and Methods. The combination of liposomal honokiol and DDP (A) 
apparently reduced the number of the microvessels, compared with the control groups, including liposomal honokiol (B), cispl-
atin (C), liposome (D) or PBS (E) alone. Vessel density was determined by counting per high-power (F).Column, the mean of the 
microvessels per high-power field; bars, ± SD. H and L mean liposomal honokiol and liposome alone respectively.BMC Cancer 2008, 8:242 http://www.biomedcentral.com/1471-2407/8/242
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of angiogenesis in the combined treatment. This sugges-
tion is supported by the present findings. The more appar-
ent apoptotic cells in the tumors treated with liposomal
honokiol plus DDP was found in fluorescent in situ
TUNEL assay, compared with the treatment with control
groups, including PBS, liposome, honokiol or DDP alone.
In addition, the combination of liposomal honokiol and
DDP apparently reduced the number of vessels by immu-
nolabeling of CD31 in the tissue sections, compared with
control groups. DDP has been effective in inducing apop-
tosis in variety of tumor cell lines [13,16-18]. Its apopto-
sis-inducing effects are known to be correlated with DNA
damage by forming DNA-Pt adducts and DNA strand
breaks. It has been reported that DNA synthesis of human
umbilical endothelial cells was in vitro inhibited by DDP
in a dose-dependent fashion, and that rabbit corneal neo-
vascularization in vivo was also suppressed by intrave-
nous injection of DDP, suggesting that DDP might have
an indirect anti-neoplastic effect through the suppression
of neovascularization required for the tumor growth [19].
Recently, evidence indicated that honokiol directly trig-
gered the apoptosis in variety of human cancer cells by the
Induction of the apoptosis in vivo Figure 3
Induction of the apoptosis in vivo. Sections from the tumor-bearing mice treated with liposomal honokiol and DDP (A), lipo-
somal honokiol (B), cisplatin (C), liposome (D) or PBS (E) alone were stained with FITC-dUTP as described in Materials and 
Methods. Apoptotic nuclei (green) were identified by TUNEL staining with FITC-dUTP and observed under a fluorescence 
microscope (× 200). The treatment with liposomal honokiol and DDP showed apparent apoptotic cells within the tumors, 
compared treatment with the control groups. Data for the quantitative assessment of apoptosis was expressed as the mean 
apoptotic index ± SDs (F). H and L mean liposomal honokiol and liposome alone respectively.
The concentration-time curve of honokiol in plasma both  liposomal honokiol and free honokiol Figure 4
The concentration-time curve of honokiol in plasma both 
liposomal honokiol and free honokiol. Mice were i.v. treated 
by liposomal or free honokiol at a dose of 25 mg/kg, as 
described in Materials and Methods. The honokiol in plasma 
was detected as described in Materials and Methods. Lipo-
somal honokiol (open circle), free honokiol (solid circle).BMC Cancer 2008, 8:242 http://www.biomedcentral.com/1471-2407/8/242
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induction of caspase-dependent and -independent apop-
tosis [8,9]. It has been also reported that honokiol may be
a potent inhibitor of angiogenesis and may inhibit angio-
genesis by interfering with phosphorylation of VEGFR2 in
human endothelial cells [4]. In addition, it was also
reported that the invasion (MMP-9, IAM-1) and angiogen-
esis (VEGF) were down-regulated by honokiol [20]. Thus,
we may speculate that besides the direct apoptotic effect of
both liposomal honokiol and DDP on tumor cells them-
selves, the antiangiogenesis activity by liposomal
honokiol and DDP may as well play a partial role in the
antitumor activity by retarding or preventing adequate
nourishment of tumors during their regrowth after a
chemotherapeutic insult, resulting in tumor growth stasis.
The other findings have shown that honokiol in the com-
bination with low-dose docetaxel enhanced the inhibi-
tion of the growth and bone metastasis in prostate tumor
[21] and enhanced the cytotoxicity induced by fludarab-
ine, cladribine, or chlorambucil in B-cell chronic lym-
phocytic leukaemia (B-CLL) cells [22]. Furthermore, it
was known that the combination of an antiangiogenic
agent such as CXC Chemokine Ligand 10 [13], vascular
endothelial growth factor receptor-2 antibody [23],
squalamine [24], etc., with chemotherapy can enhance
tumor growth inhibition. Taken together, these findings
mentioned above also support our suggestion that the
enhanced antitumor efficacy in the present study may in
part result from the increased induction of the apoptosis
as well as the increased inhibition of angiogenesis in the
combined treatment.
It has been known that A549 cells have a mutant active
Ras oncogene [25]. Our data suggest that honokiol alone
had the antitumor activity against human lung cancer in
A549 lung cancer xenograft model, and that the combina-
tion of honokiol with DDP can enhance the antitumor
activity. It has also been reported that the mutant K-ras
blocks the efficacy of targeted EGFR inhibitors, like iressa
and tarceva [26]. Therefore, whether or not honokiol
could sensitize A549 cells to these agents is an intriguing
question to be further explored.
The preparation of the clinically available honokiol has
been limited by its poor solubility. We have found that
except for dimethylsulfoxide, honokiol was seldom
solved in the other solvents available to the preparation of
the drugs. However, there are concerns about using higher
doses of dimethylsulfoxide, as it causes the dose-depend-
ent hemolysis, it is harmful to the liver and kidneys, and
it has an unpleasant odor for 48 hours after the adminis-
tration [27-29]. In the present study, we encapsulated
honokiol as PEG-PE modified liposome nanoparticle,
since liposomes have been used previously as carriers for
delivery of a variety of drugs, including antibiotic, anti-
fungal, and cytotoxic agents [30,31]. In the present study,
we found that honokiol-encapsulated liposome has
shown the improvement in the solubility of honokiol and
the prolongation of its circulation time in plasma. The
management of unresectable lung cancers remains a
major therapeutic challenge to medical oncologists [1,3].
The present study has demonstrated that liposomal
honokiol had the inhibitory effect on the growth of
human lung cancer in A549 lung cancer xenograft model,
and that liposomal honokiol plus DDP induced the
enhanced antitumor activity without adverse conse-
quences found. Thus, our observations may have poten-
tial implications for the treatment of human lung cancer
by liposomal honokiol plus DDP.
Conclusion
In summary, our data suggest that that liposomal
honokiol alone had the antitumor activity against human
lung cancer in A549 lung cancer xenograft model, and that
the combination of honokiol with DDP can enhance the
antitumor activity, and that the enhanced antitumor effi-
cacy in vivo may in part result from the increased induc-
tion of the apoptosis and the enhanced inhibition of
angiogenesis in the combined treatment. The present
findings may be of importance to the further exploration
of the potential application of the liposomal honokiol
alone or the combined approach in the treatment of lung
carcinoma.
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Table 1: The representative experiment of hematologic evaluation
RBC (106/μl) Platelets(106/μl) WBC(103/μl) Neutrophils(103/μl) Lymphocytes(103/μl)
Saline 10.8 ± 1.7 1.6 ± 0.2 10.8 ± 3.2 4.1 ± 2.2 4.6 ± 2.5
Honokiol 9.2 ± 2.1 1.6 ± 0.4 10.2 ± 2.4 4.0 ± 1.5 4.2 ± 1.8
DDP 9.2 ± 2.6 1.5 ± 0.5 8.9 ± 2.1 3.6 ± 1.3 3.2 ± 2.3
Honokiol
plus DDP 9.1 ± 3.3 1.5 ± 0.7 8.8 ± 2.8 3.8 ± 1.7 3.3 ± 1.9
RBC, platelets, WBC, neutrophils and lymphocyte counts were performed before therapy and at weekly intervals for 4 weeks. The administration 
of liposomal honokiol plus DDP was described in the Materials and Methods section, The treatment with honokiol, DDP or the combined did not 
show the significant decrease of the cell counts on day 14 after the therapy, compared with saline alone(P > 0.05), as shown in the table. The similar 
results were found on day 7, 21, 28 after the therapy.BMC Cancer 2008, 8:242 http://www.biomedcentral.com/1471-2407/8/242
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